Antifungals Market Report 2025

This Antifungals market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The antifungals market size has grown strongly in recent years. It will grow from $27.01 billion in 2024 to $29.67 billion in 2025 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to fungal disease prevalence, aging population, healthcare infrastructure, awareness and education.

The antifungals market size is expected to see strong growth in the next few years. It will grow to $41.84 billion in 2029 at a compound annual growth rate (CAGR) of 9%. The growth in the forecast period can be attributed to emerging fungal strains, regulatory approvals, global health concerns, increased healthcare spending, patient education and awareness. Major trends in the forecast period include research and development, telemedicine and e-health, advancements in antifungal drug development, collaborations and partnerships.

The growing prevalence of fungal infections is expected to drive the growth of the antifungals market in the coming years. Fungal infections are diseases caused by the invasion and growth of fungi in or on the body. Fungi can affect various body parts, including the skin, nails, lungs, and mucous membranes. The rise in fungal infections is attributed to factors such as the increasing number of immunocompromised individuals, climate change creating more favorable environments for fungal growth, greater use of broad-spectrum antibiotics disrupting natural microbiomes, poor hygiene, urbanization, and the growing prevalence of chronic conditions like diabetes, which make individuals more susceptible to fungal infections. Antifungals are vital in treating fungal diseases by inhibiting the growth and reproduction of fungi, either by disrupting their cell wall or membrane, blocking essential enzymatic processes, or interfering with their ability to synthesize vital components, thus reducing fungal load, alleviating symptoms, and preventing the spread of infection. For instance, in September 2024, the International Society for Infectious Diseases, a US-based non-profit organization, reported an annual incidence of 6.5 million invasive fungal infections, leading to approximately 3.8 million deaths, with 2.5 million (68%; range 35-90%) directly attributable to these infections. As a result, the increasing occurrence of fungal infections is anticipated to fuel the growth of the antifungals market.

The expansion of healthcare infrastructure is expected to drive the growth of the antifungals market. Healthcare infrastructure includes the physical and organizational structures, facilities, and systems that facilitate the delivery of healthcare services. It encompasses the essential facilities, systems, and resources required for the effective management of fungal infections. For example, in May 2023, according to the Office for National Statistics, a UK-based government body, the healthcare spending in the UK reached approximately $347.74 billion in 2022, reflecting a nominal increase of 0.7% compared to the previous year. This investment in healthcare infrastructure is anticipated to play a significant role in propelling the growth of the antifungals market in the future.

Drug developers and manufacturers in the anti-infective drugs market are increasingly focusing on expanding their operations by strengthening various departments, including research and development, marketing, and manufacturing. They are achieving this through collaborative efforts and strategic partnerships with other companies and research institutes. These collaborations enable them to diversify their product portfolios and stay competitive in the market while increasing their revenues. Therefore, companies operating in the anti-infective drugs market should seriously consider the potential benefits of strategic collaborations. Such partnerships can help them broaden their product offerings, enhance their market presence, and ultimately drive higher revenues, ensuring their continued competitiveness in the market.

Major companies in the antifungals market are actively involved in product innovation to enhance their profitability. One notable innovation is the development of Supra Bioavailable Itraconazole, an advanced formulation of the antifungal medication itraconazole aimed at improving its bioavailability and efficacy in the treatment of fungal infections. For example, in June 2022, Apex Labs, an India-based pharmaceutical company, introduced Supra Bioavailable Itraconazole in 65 and 130 mg capsules. These capsules deliver a higher proportion (90 percent) of the active medication to the body's biological system, necessitating lower dosages. This reduction in inter-individual variability holds the potential for enhanced effectiveness in the treatment of fungal infections. Such innovations play a crucial role in strengthening a company's position and profitability in the antifungals market.

Major companies operating in the antifungals market include Pfizer Inc., Novartis International AG, Merck & Co. Inc., Bayer AG, Abbott Laboratories, Sanofi S.A., Kramer Laboratories Inc., GlaxoSmithKline PLC, Gilead Sciences Inc., Basilea Pharmaceutica AG, Sigma-Aldrich, Astellas Pharma Inc., Janssen Pharmaceutica NV, Zydus Cadila Healthcare Ltd., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Scynexis Inc., Mayne Pharma Inc., Cosmo Pharmaceuticals NV, Leadiant Biosciences Inc., Glenmark Pharmaceuticals Limited, Cidara Therapeutics, MATINAS BIOPHARMA, Mylan N.V., Perrigo Company PLC, Wockhardt Ltd., Lupin Limited, Dr. Reddy's Laboratories Ltd., Torrent Pharmaceuticals Ltd., Hikma Pharmaceuticals PLC, Mayne Pharma Group Limited, Fresenius Kabi AG, Baxter International Inc., Akorn Operating Company LLC, Amphastar Pharmaceuticals Inc., Mylan Institutional LLC, West-Ward Pharmaceuticals Corp., Gland Pharma Limited, Aurobindo Pharma Limited.

Antifungal drugs are pharmaceuticals designed to detect and eradicate fungal pathogens, particularly in conditions arising from unsanitary environments. These medications, also referred to as antimycotic drugs, serve to treat and prevent fungal infections like athlete's foot, ringworm, candidiasis (thrush), and more severe systemic conditions such as cryptococcal meningitis.

The primary categories of antifungal drugs include echinocandins, azoles, polyenes, and allylamines. Echinocandins represent a novel class of antifungal medications that operate by specifically inhibiting the formation of 1,3-D-glucan, a crucial component of the fungal cell wall. Antifungals can be administered through various routes, including oral, parenteral, and topical methods, and they cater to therapeutic indications such as aspergillosis, dermatophytosis, candidiasis, among others. These drugs find applications in various sectors, including hospitals and clinics, dermatology clinics, and other user groups.

The antifungals market research report is one of a series of new reports that provides antifungals market statistics, including antifungals industry global market size, regional shares, competitors with antifungals market share, detailed antifungals market segments, market trends, and opportunities, and any further data you may need to thrive in the antifungals industry. This antifungals market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

North America was the largest region in the drugs for antifungals market in 2024. The Middle East is expected to be the fastest-growing region in the antifungals market. The regions covered in the antifungals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antifungals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The antifungal market consists of sales of clotrimazole, miconazole, and ketoconazole. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.